A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice

Amir Jazaeri*, Robert L. Coleman, Anil K. Sood, Michael M. Frumovitz, Pamela T. Soliman, Aaron Shafer, Jeffry J. Cutrera, Marlana Klinger, Sara E. Sharafi, Cynae A.L. Johnson, Valerie F. Villanueva, Emily M. Hinchcliff, Andrea Dickens, Katherine E. Cain, Jaime E. Anderson, Karen H. Lu, Shannon N. Westin

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

The success of targeted and immune therapies in other malignancies has led to an exponential increase in the number of active and pending clinical trials using these therapeutic approaches in patients with gynecologic cancers. These novel investigational agents are associated with unique and potentially life-threatening toxicities and many require special multidisciplinary logistical considerations. The objective of this review is to describe a practical approach for the safe implementation of targeted and immune therapies in academic gynecologic oncology practices based on our experience at M.D. Anderson Cancer Center.

Original languageEnglish (US)
Pages (from-to)374-380
Number of pages7
JournalGynecologic oncology
Volume151
Issue number2
DOIs
StatePublished - Nov 2018

Keywords

  • Adoptive cell therapy
  • Checkpoint inhibitor
  • Clinical trials
  • Immune-related adverse events
  • Immunotherapy
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice'. Together they form a unique fingerprint.

Cite this